公开(公告)号：US20240277828A1

公开(公告)日：2024-08-22

申请号：US18653422

申请日：2024-05-02

Applicant: SANOFI PASTEUR INC

Inventor： Timothy ALEFANTIS ,  Mario BARRO ,  Anthony BYERS ,  Guadalupe CORTES-GARCIA ,  Philippe-Alexandre GILBERT ,  Harold KLEANTHOUS ,  Armaghan NAIK ,  Konstantin PUGACHEV ,  Saranya SRIDHAR ,  Thorsten VOGEL ,  William WARREN

IPC: A61K39/145 ,  A61K39/00 ,  A61P37/04

CPC classification number: A61K39/145 ,  A61P37/04 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70

Abstract: Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

公开(公告)号：US20210128715A1

公开(公告)日：2021-05-06

申请号：US17041784

申请日：2019-03-27

Applicant: SANOFI PASTEUR INC.

Inventor： Tod STRUGNELL ,  Eliud OLOO ,  Raymond OOMEN ,  Thorsten VOGEL ,  Harold KLEANTHOUS

IPC: A61K39/145 ,  C07K14/11 ,  A61P31/16

Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.

公开(公告)号：US20240335525A1

公开(公告)日：2024-10-10

申请号：US18682372

申请日：2022-08-10

Applicant: SANOFI PASTEUR INC.

Inventor： Mario BARRO ,  Yvonne CHAN ,  Guadalupe CORTES-GARCIA ,  Raul GOMILA ,  Liqun HAN ,  Justin KLEKOTA ,  Fuqin MA ,  Satyajit RAY ,  Svetlana STEGALKINA ,  Tod STRUGNELL ,  Irina USTYUGOVA ,  Thorsten VOGEL ,  Jianxin ZHANG

IPC: A61K39/145 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  C07K14/705 ,  C12N9/24

CPC classification number: A61K39/145 ,  A61P37/04 ,  C07K14/005 ,  C07K14/70596 ,  C12N9/2402 ,  C12Y302/01018 ,  A61K2039/645 ,  C07K2319/02 ,  C12N2760/16134

Abstract: Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.